2026³â 05¿ù 01ÀÏ ±Ý¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Center for Disease Analysis Foundation Receives $7 Million Grant from the John C. Martin Foundation to Support the Polaris Observatory

´º½ºÀÏÀÚ: 2024-11-22

LAFAYETTE, COLO. -- The Center for Disease Analysis (CDA) Foundation announced receipt of a $7 million grant from the John C. Martin Foundation to sustain and expand the Polaris Observatory until the end of 2030.

The Polaris Observatory serves as the definitive source for global data on hepatitis B and C virus (HBV and HCV) burden, providing insights into the prevalence and distribution of these viruses across countries, regions, and globally. It also assists national governments and international organizations in monitoring progress toward the World Health Organization’s (WHO) 2030 elimination targets for HBV and HCV. Annually, the Observatory collaborates with over 1,000 national experts in 120 countries, updating forecasts for each country. Additionally, it offers pro bono support to national governments, assisting them in developing and implementing elimination programs and strategies to fund for their initiatives.

“We are deeply grateful for the John C. Martin Foundation’s unwavering support,” expressed Homie Razavi, Managing Director of the CDA Foundation. “Their initial funding in 2015 catalyzed the establishment of the Polaris Observatory, and their continuous support has enabled us to sustain our work. The Observatory’s programs are supported by a dedicated team of epidemiologists, mathematical modelers, programmers, and decision analysts. The Observatory’s contributions have resulted in nationally funded access to hepatitis screening for 1.7 billion people globally, laboratory testing (24 million people), and treatment (19 million people) as result of recognized value of early detection and treatment. This new grant will facilitate our continued efforts through 2030.”

“On behalf of the John C. Martin Foundation, it is a privilege to support the CDA Foundation in the past decade to service the international hepatitis elimination collaborators. We are grateful for the opportunity to support such an impactful and momentous program,” said Dr. Lillian Lou, President, Program Director of the John C. Martin Foundation (https://thejcmfoundation.org).

CDA Foundation is a nonprofit organization focused on accelerating hepatitis B and C elimination through verified epidemiological data, disease burden and economic impact modeling, intervention strategies, innovative financing, and knowledge-sharing partnerships. It accomplishes these goals through the Polaris Observatory (https://cdafound.org/polaris/).



 Àüü´º½º¸ñ·ÏÀ¸·Î

NetApp and Commvault Advance Cyber Resilience with Strategic Alliance
RSA Announces Expanded Partnership with Microsoft, Enhances Leadership in Passwordless Identity Security
Hytera to Host Global Partner Summit 2026 in Shanghai, Advancing AI-Powered Mission-Critical Communications
XBOW Raises $120M to Scale its Autonomous Hacker
SES Taps K2 Space to Accelerate Next-Gen MEO Satellite Network, meoSphere
Biocytogen Grants Taisho Pharma License for RenNano Human Heavy Chain-Only Antibody Platform
SAP and S3NS Accelerate Trusted Cloud Adoption in France With Thales as First Strategic Customer

 

Black Hat Asia 2026 Reveals AI Security and Cloud Insights as APAC Fir...
Askey and Canoga Perkins Partner at MWC Barcelona to Deliver Rapid-Dep...
LYCRA¢ç ANTISTATIC Fiber Debuts at Techtextil, Bringing Advanced Comfo...
Cognite Positioned as a Front Runner in LNS Research Solution Selectio...
LG Electronics Showcases AI Data Center Cooling Solutions at Data Cent...
MariaDB Completes GridGain Acquisition to Power the Next Generation of...
Rubedo Life Sciences Reports Positive Phase 1 Results for RLS-1496 in ...

 


°øÁö»çÇ×
´º½ºÁö Áß¹®Ç¥±â´Â À½Â÷ Ç¥±â¹æ½Ä '纽ÞÙó¢ ´Ï¿ì½ºÁö'
'º£³×ÀÍ' Áß¹® Ç¥±â 宝Ò¬ìÌ, 'À̺ñÁî: ÀÌÁö' Áß¹® Ç¥±â æ¶币òª...
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®À¯ºñ Alliuv ä¹备: ä¹êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØ, À£ÇÁ·Ò Welfrom 卫ÜØ
¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备 äþÒöêóÝá
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØ ä¹ì³ÜØ

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..